Drugs that contain Betamethasone Dipropionate; Calcipotriene
1. Enstilar patents expiration
ENSTILAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(7 years from now) | |
|
US10130640 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(7 years from now) | |
|
US9119781 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jan 30, 2023 |
| New Patient Population(NPP) | Jul 30, 2022 |
| New Product(NP) | Oct 16, 2018 |
Market Authorisation Date: 16 October, 2015
Treatment: Plaque psoriasis; Topical treatment of plaque psoriasis in patients 12 years and older
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of ENSTILAR before it's drug patent expiration?
More Information on Dosage
ENSTILAR family patents
2. Taclonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763426 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| USRE39706 | LEO PHARMA AS | Crystalline form of a vitamin D analogue |
Jun, 2015
(8 years ago) | |
| US6753013 | LEO PHARMA AS | Pharmaceutical composition |
Jan, 2020
(4 years ago) | |
| US6787529 | LEO PHARMA AS | Topical composition |
Jan, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 23, 2017 |
Market Authorisation Date: 09 January, 2006
Treatment: Treatment of moderate plaque psoriasis
Dosage: SUSPENSION;TOPICAL
How can I launch a generic of TACLONEX before it's drug patent expiration?
More Information on Dosage
TACLONEX family patents
3. Wynzora patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265265 | MC2 | Topical composition |
Sep, 2027
(3 years from now) | |
| US11638711 | MC2 | NULL |
Mar, 2039
(14 years from now) | |
| US11696919 | MC2 | Topical composition |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 20, 2023 |
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
More Information on Dosage
WYNZORA family patents